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Background: An etiological role for immune factors operating during early brain
development in children with autism spectrum disorders (ASD) has not yet been
established. A major obstacle has been the lack of early biologic specimens that can
be linked to later diagnosis. In a prior study, we found lower risk of ASD associated
with higher levels of maternally-derived total IgG and Toxoplasmosis gondii (Toxo) IgG
in newborn blood spot specimens from children later diagnosed with ASD compared to
population controls.
Methods: We obtained maternal mid-gestational serum specimens and newborn
screening blood spots from the California Genetics Disease Screening Program (GDSP)
for linked mother-baby pairs for 84 children with ASD and 49 children with developmental
delay but not ASD (DD) identified from California Department of Developmental Services
records and for 159 population controls sampled from birth certificates.Immunoglobulin
levels in maternal and newborn specimens weremeasured by solid phase immunoassays
and analyzed in logistic regression models for total IgG, total IgM, and Toxo IgG, and, for
maternal specimens only, Toxo IgM. Correlations between maternal and newborn ranked
values were evaluated.
Results: In both maternal and newborn specimens, we found significantly lower risk
of ASD associated with higher levels of Toxo IgG. In addition, point estimates for all
comparisons were <1.0 suggesting an overall pattern of lower immunoglobulin levels
associated with higher ASD risk but most did not reach statistical significance. We did
not find differences in maternal or newborn specimens comparing children with DD to
controls.
Discussion: These results are consistent with evidence from our prior study and other
published reports indicating that immune factors during early neurodevelopment may be
etiologically relevant to ASD. Lowered immunoglobulin levels may represent suboptimal
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function of the maternal immune system or reduced maternal exposure to common
infectious agents.
Conclusion: Patterns seen in these selected immunoglobulins may provide clues
to mechanisms of early abnormalities in neurodevelopment contributing to ASD.
We recommend further study of immunoglobulin profiles in larger samples of linked
mother-baby pairs to evaluate possible etiologic relevance.
Keywords: autism, maternal infection, biomarkers, immune function
INTRODUCTION
Whether and how immune factors operating during fetal
brain development are etiologically relevant to autism spectrum
disorders (ASD) has not yet been determined. Numerous
studies have documented atypical immune findings in some
individuals already diagnosed with ASD. These include post-
mortem brain tissue studies demonstrating evidence of chronic
CNS inflammation in individuals aged 4–40 years old with
ASD (Goines and Van de Water, 2010; Onore et al., 2012).
More directly implicating a prenatal etiologic pathway, animal
model studies have shown that autism-relevant behaviors can be
induced in offspring following in utero exposure to antibodies
derived from mothers with a child already diagnosed with
ASD (Martin et al., 2008; Singer et al., 2009; Braunschweig
et al., 2012), but not prenatal exposure to antibodies derived
from serum of children with ASD (Morris et al., 2009).
Other animal studies provide evidence that activation of the
maternal immune system during pregnancy, either through
infectious or non-infectious agents, can lead to atypical behaviors
similar to those in ASD-affected children (Patterson, 2011).
These findings are consistent with observational human studies
that report maternal viral exposure (Chess, 1971; Deykin
and MacMahon, 1979; Markowitz, 1983; Stubbs et al., 1984;
Yamashita et al., 2003; Atladottir et al., 2012a; Zerbo et al., 2013)
or inflammation (Brown et al., 2014) during pregnancy to be
associated with increased risk of ASD in some children. Evidence
for an association between prenatal infection and risk of other
psychiatric disorders, such as schizophrenia and bipolar disorder,
has also been reported (Buka et al., 2001a, 2008; Brown, 2011;
Mortensen et al., 2011; Kneeland and Fatemi, 2013).
Despite this growing and complex body of research, questions
regarding an etiologic role for immune factors in ASD remain to
be resolved, impeded, in part, by a paucity of biologic specimens
obtained during the presumed vulnerable period of fetal brain
Abbreviations: ASD, autism spectrum disorders; CNS, central nervous system;
DDS, California Department of Developmental Services; CAT, category; CPD,
The Center for Persons with Disabilities (CPD); DD, developmental delay; DSM
IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; ELISA,
enzyme-linked immunosorbent assay; EMA, Early Markers for Autism Study;
GA, gestational age; GDSP, California Genetics Disease Screening Program;
HIGH, the three higher quartiles (or categories); IgA, Immunoglobulin A; IgG,
Immunoglobulin G; IgM, Immunoglobulin M; IRB, institutional review board;
LOW, lowest quartile (or category); MDL, minimum detection level; OR, odds
ratio; PBB, Project Baby’s Breath; Q, quartile; RCOC, Regional Center of Orange
County; SI, standardized international units; Toxo, Toxoplasmosis gondii; XAFP,
expanded alpha fetoprotein.
development and linked to later behaviorally-based diagnostic
information. Routinely collected and archived specimens in
California provide a resource for addressing some of these
questions.
Using archived maternal specimens from California originally
obtained during routine prenatal screening (Early Markers for
Autism Study/EMA), Croen et al. (2008a) found differences
in maternal mid-gestation antibody reactivity to human fetal
brain protein in specimens from mothers of children with
ASD compared to population-based controls. Although, the
differences did not reach statistical significance, they are generally
consistent with those based on maternal specimens obtained
after an ASD diagnosis of an affected child (Dalton et al., 2003;
Zimmerman et al., 2007; Braunschweig et al., 2008). Using the
same prenatal specimens from the EMA project, Goines et al.
(2011) reported a pro-inflammatory cytokine profile in mothers
of children with ASD that was different from that of mothers of
children without ASD.
In another California study, we measured neonatal levels
of selected IgG, IgM, and IgA antibodies in archived newborn
screening blood specimens to evaluate the hypothesis that higher
antibody levels would be associated with a risk of ASD (Grether
et al., 2010). In newborns, IgG antibodies are largely derived
from the mother and transferred across the placenta to the
fetus (Simister, 2003). Neonatal IgM and IgA antibodies are
generally made by the fetus or neonate and serve as one
set of putative markers of perinatal infection. In this earlier
California study (Grether et al., 2010) in which we evaluated
total IgG, IgM, and IgA as well as common viral antigen-
specific immunoglobulins, we found no evidence of elevated
immunoglobulin levels that would indicate increased prenatal
infectious exposure in children with ASD, but we could not
confidently rule out a role for all possible antigens or early
transient exposures. Contrary to our hypothesis and of uncertain
clinical significance, we found significantly lower ASD risk
associated with higher levels of total IgG and Toxoplasmosis
gondii (Toxo) IgG in the newborn specimens from the children
with ASD. If supported by further research, these results may
plausibly represent suboptimal humoral function in the maternal
immune system and/or impaired transplacental transfer; the
findings may also represent a protective effect in the controls in
the postnatal period from earlier maternal exposure. As maternal
specimens were not available for the children in that study, we
were unable to further explore possible pathways.
We here report a case-control study using maternal
mid-gestational as well as neonatal specimens from linked
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mother-child pairs to re-evaluate total IgG, total IgM,
and Toxoplasma gondii immunoglobulins in children with
ASD compared to population-based controls. To assist with
interpretation of results, we also included a group of children
with other developmental disabilities, comparing their assay
results to control values. The study sample comes from the Early
Markers for Autism (EMA) Study, a population-based, nested
case-control study designed to evaluate biologic markers of
susceptibility and exposure in archived maternal mid-gestational
and neonatal blood specimens from linked mother-baby pairs.
METHODS
Subjects
Study subjects were selected from the population of offspring
born to women living in Orange County, California who were
pregnant in 2000–2001 and enrolled in the State’s Prenatal
Expanded Alphafetoprotein Screening Program (Croen et al.,
2008a) and for which specimens were available in the Project
Baby’s Breath (PBB) special research archive (see below). Three
groups of children were identified: children with ASD, children
with other developmental delay but not ASD (DD), and general
population controls. Children with ASD or DD represent all
children identified with these conditions who met the above
criteria and who were enrolled with the Regional Center of
Orange County (RCOC), one of 21 Regional Centers operated
by the California Department of Developmental Services (DDS)
to coordinate services for persons with ASD, developmental
delay, and other developmental disabilities. Possible ASD cases
were initially ascertained as clients receiving DDS services for
autistic disorder or clients receiving services for other DDS-
eligible conditions but who also had a code indicating ASD in
the electronic record. Possible DD cases were initially ascertained
as DDS clients without any evidence of ASD in the electronic
records and with evidence of intellectual disability.
To confirm ASD or DD case status, we followed a
protocol initially developed by the Metropolitan Atlanta
Developmental Disabilities Surveillance Program (Autism and
Developmental Disabilities Monitoring Network Surveillance
Year 2006 Principal Investigators; Centers for Disease Control
and Prevention (CDC), 2009), employing trained medical record
abstractors to compile detailed diagnostic and clinical data from
RCOC records for all children ascertained as possible ASD or
possible DD. A pediatrician with certification in developmental
and behavioral pediatrics (RH) then conducted expert clinical
review of abstracted data to confirm ASD or DD case status
using DSM IV criteria. Because of etiologic questions regarding
co-morbid intellectual disability in children with ASD, children
with ASD were further categorized by presence or absence
of intellectual disability using DSM-IV criteria and based on
standardized cognitive and adaptive assessments. Children with
all scores <70 were coded as having ID; children with all scores
≥70 or some scores <70 and others ≥70 were coded as not
having ID; children with no standardized scores in their chart
were coded as “unknown.”
Controls were randomly sampled from the birth certificate
files, frequency matched to ASD cases by sex, birth month, and
birth year in a 2:1 ratio; all past or current DDS clients were
identified through statewide electronic files and excluded from
the control population. Demographic variables for all subjects
were obtained from live birth certificates.
Specimen Collection
Maternal mid-gestational specimens were retrieved from the
Project Baby’s Breath (PBB) prenatal screening specimen archive
maintained by the California Genetic Disease Screening Program
(GDSP), California Department of Public Health. Following the
completion of routine prenatal screening conducted by GDSP,
PBB had retained any remaining portions of specimens in three
selected southern California counties and selected birth years
for analysis in approved research studies. During the study
period, prenatal screening was conducted for approximately
70% of pregnancies in the state (state law mandates that all
women in the first half of pregnancy be offered the voluntary
screening). Venous blood was collected at 15–20 weeks gestation
in serum separator tubes by obstetrical care service providers and
laboratories, and underwent expanded alpha fetoprotein (XAFP)
screening at a single regional laboratory, typically within 7 days
of collection (median time = 3 days). During transit via US
Postal Service to the regional screening laboratory, no effort was
made to control the temperature of the specimens. After testing,
remaining portions of specimens were kept under refrigeration
for 1–2 days and then stored at−20◦C by the regional laboratory
and PBB. Aliquots of the samples used for this study were shipped
to the laboratory of Dr. Judy van de Water, UC Davis, and stored
at −80◦C until use with a single thaw prior to immunoglobulin
testing. All samples were exposed to the same collection and
storage protocols.
Newborn screening filter paper blood specimens were
obtained from the newborn archive maintained by GDSP that
conducts routine metabolic screening for all newborns in the
state. Specimens from cases and controls were located, one spot
bar-coded with a study identifier, and shipped on dry ice, without
regard to case-control status, to The Center for Persons with
Disabilities (CPD) at Utah State University. Working under
aseptic conditions, researchers in the CPD lab prepared 96-well
plates, each well containing two 3mm diameter punches from
one archived specimen. Since original blood draw and newborn
screening, specimens have been stored at−20◦C.
All prenatal and newborn specimens were then shipped on
dry ice to the Neurovirology Laboratory, Johns Hopkins School
of Medicine, for analysis, blinded to case-control status, using
enzyme immunoassays as described below.
Laboratory Assays
We measured antibodies in both maternal and newborn
specimens by solid phase immunoassays (ELISA). Maternal and
newborn total IgG and total IgM levels were expressed as
µg/ml. In maternal specimens, we also measured Toxoplasma
gondii (Toxo) IgG with resulting levels expressed as standardized
international units (SI) and Toxo IgM with resulting levels
expressed as blank-adjusted optical density units. In newborn
specimens, wemeasured Toxo IgGwith resulting levels expressed
as blank-adjusted optical density units. Assay results were not
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corrected for hematocrit or total protein and specimens lacking
detectable signals for a specific assay were considered at the
minimum detection level (MDL) for that assay.
Exclusions
Subjects (1 child with ASD, 3 children with DD, 1 control child)
were excluded due to estimated gestational age <26.0 completed
weeks (182 days; recorded on the birth certificate and based on
LMP) or because age at blood draw was >7.0 days after birth
according to the newborn screening record.
Statistical Methods
To take into consideration assay detection limits, unknown
distributions of the immunoglobulins, and inadequate
knowledge of the biologic significance of immunoglobulin
levels measured in archived specimens, we conducted primary
analyses treating the measured immunoglobulin values as
categorical variables. Categories were constructed separately for
each of the analytes based on percent of signals at the MDL for
these assays: if ≤25% of controls were at the MDL, observations
were divided into quartiles based on control values, with MDL
values included in lowest quartile (Q1); if >25% of controls
had values at the MDL, then MDL values were designated as
the lowest category (CAT1) and remaining values were divided
into three equal-sized categories based on control values. The
exception to this was newborn total IgM, which had only a low
and a high category due to limited distribution.
For comparisons between ASD and controls, and separately
between DD and controls, we then conducted crude and adjusted
analyses using logistic regression to estimate the risk of ASD
(or DD) associated with each analyte separately, comparing the
lowest category to each higher category using odds ratios (ORs)
considered statistically significant if 95% confidence intervals
did not include 1.0. Adjusted models included assay plate (5
maternal and 5 newborn) as additional independent variables and
covariates associated with ASD (or DD) in these data (p < 0.5;
Table 1). Due to small numbers of childrenwithDD, we collapsed
the three higher quartiles (or categories) into one group (HIGH)
and used the lowest quartile (or category) as the reference
group (LOW).We explored differences in immunoglobulin levels
between children with ASD with ID and those with ASD without
ID, comparing each of these subgroups to the control group.
Small numbers of subjects in subgroups precluded the use of
adjusted models.
To evaluate the association between maternal mid-gestational
analyte signals and those detected in their children’s newborn
specimens, we computed Spearman rank-order correlation
coefficients separately for cases and controls for the three analytes
measured in both mothers and newborns (total IgG, total
IgM, and Toxo IgG). Values at the MDL were treated as the
lowest category, with measured signals above the MDL for each
individual treated as categorical variables in the computations.
Institutional Review Board
This study was approved by the California Health and Human
Services Agency Committee for the Protection of Human
Subjects (IRB) and the Kaiser Permanente of Northern California
Institutional Review Board, who granted a waiver of informed
consent. The analytic laboratories operated under an IRB
exemption as the samples were preexisting and did not have
personal identifiers.
RESULTS
The final study group included 84 children with ASD, 49 children
with DD, and 159 controls. No significant differences were
found between ASD and controls on the matching variables
(gender, birth month, birth year), nor for single or multiple
birth, gestational age (GA), birth weight, days between birth and
blood draw, and protein concentration in the newborn specimen
(Table 1). Mothers of children with ASD were similar to controls
with regard to parity, inter-pregnancy interval (number of
months between birth of index child and prior live birth), GA
at mid-gestational blood draw, and maternal weight at blood
draw (Table 1). ASD cases were more likely than controls to have
mothers who self-identified as white non-Hispanic, were older,
and more educated.
Compared to the control children, children with DD were less
likely to be male and born in the first study year (2000) or during
the same birth months due to matching of the controls with
the ASD group on these variables. Children with DD were also
of lower birth weight and had a longer time between birth and
blood draw than controls (Table 1). No differences in maternal
characteristics were observed.
For the ASD study group, both newborn and maternal
specimens were available for 80 mother-baby pairs and only
maternal specimens were available for the remaining 4 mother-
baby pairs; for the DD study group, both specimens were
available for 45 pairs, only maternal specimen for 1 pair, and only
newborn specimens for 3 pairs; for the controls, both specimens
were available for 141 pairs, only maternal specimens for 6 pairs,
and only newborn specimens for 12 pairs. Signals above theMDL
were detected for total IgG and total IgM in all maternal and
newborn specimens and for Toxo IgM in all maternal specimens.
For the Toxo IgG assay, 93 maternal specimens were at the MDL
(45% of ASD, 33% of DD, 27% of controls), as was one newborn
specimen for a child with DD.
ASD vs. Controls
The distributions of each analyte for ASD cases and controls are
shown inTable 2. In unadjusted analyses, measured levels of total
IgG, total IgM, and Toxo IgM in mid-gestational specimens of
mothers of children diagnosed with ASD were not significantly
different from population control values but virtually all point
estimates were substantially below 1.0 (Table 2). For Toxo
IgG, significantly fewer mothers of children with ASD were
represented in CAT3 and CAT4 than were mothers of controls
(Table 2), indicating lower risk of ASD with higher measured
antibody.
In unadjusted analyses, newborn specimens from children
with ASD did not show significantly different levels from controls
for total IgG or total IgM. For Toxo IgG, risk was reduced
for signals above Q1, but only significantly so for Q2 and Q4
(Table 2). All ORs were below 1.0 in the newborn comparisons.
Frontiers in Neuroscience | www.frontiersin.org 4 May 2016 | Volume 10 | Article 218
Grether et al. Perinatal Immunoglobulin Levels and Autism
TABLE 1 | Demographic characteristics of children with Autism Spectrum Disorders (ASD), developmental delay without ASD (DD), and Control Subjects.
Early Markers for Autism (EMA) Study, births 2000, 2001.
Controls (N = 159) Children with ASD (N = 84) Children with DD (N = 49)
Baby characteristics N % N % P-valuea N % P-valuea
GENDER
Male 139 87.42 73 86.90 0.91 29 59.18 <0.0001
Female 20 12.58 11 13.10 20 40.82
BIRTH YEAR
2000 31 19.5 23 27.38 0.16 26 53.06 <0.0001
2001 128 80.5 61 72.62 23 46.94
Birth Month 0.96 0.01
PLURALITY
Singleton 156 98.11 81 96.43 0.42 47 95.92 0.34
Multiple 3.00 1.81 3 3.57 2 4.08
Mean (SD) Mean (SD) P-valueb Mean (SD) P-valueb
Gestational age at birth (days) 271.01 (14.27) 272.12 (18.47) 0.63 266.33 (28.12) 0.27
Birth weight 3348.1 (616.09) 3416.1 (699.1) 0.44 2897.7 (827.22) 0.0008
Days between birth and blood draw 1.46 (0.94) 1.48 (0.71) 0.80 1.92 (1.43) 0.036
Protein concentration in newborn specimen (ug/ml) 6520.3 (1377.2) 6495.5 (1222.1) 0.89 6404.4 (1551.5) 0.62
Maternal characteristics N % N % P-valuea N % P-valuea
MATERNAL RACE/ETHNICITY
White non-Hispanic 53 33.33 37 44.05 0.0005 9 18.37 0.43
White Hispanic: US Born 13 8.18 10 11.9 5 10.20
White Hispanic: Not US Born 60 37.74 10 11.9 23 46.94
Black 1 0.63 0 0.00 1 2.04
Asian 28 17.61 19 22.62 9 18.37
Other 4 2.52 8 9.52 2 4.08
MATERNAL AGE
<20 9 5.66 2 2.38 0.004 3 6.12 0.90
20–24 33 20.75 7 8.33 8 16.33
25–29 48 30.19 18 21.43 18 36.73
30–34 51 32.08 38 45.24 14 28.57
35+ 18 11.32 19 22.62 6 12.24
MATERNAL EDUCATION
< High school 49 30.82 7 8.43 <0.0001 22 44.90 0.23
High school graduate 39 24.53 15 18.07 9 18.37
College 46 28.93 40 48.19 14 28.57
Post graduate 25 15.72 21 25.3 4 8.16
PARITY
Primiparous 67 42.14 42 50.00 0.24 16 37.65 0.24
Multiparous 92 59.86 42 50.00 33 67.35
INTER-LIVEBIRTH INTERVAL (MONTHS)
0–12 16 17.58 8 20.00 0.68 4 12.50 0.52
13–24 19 20.88 10 25.00 10 31.25
25–60 31 34.07 15 37.50 12 37.50
>60 25 27.47 7 17.50 6 18.75
Mean (SD) Mean (SD) P-valueb Mean (SD) P-valueb
Gestational age at blood draw (days) 118.78 119.76 0.35 118.37 0.75
Mother’s weight at XAFP blood draw (lbs) 146.89 (33.78) 145.07 (26.72) 0.65 150.3 (39.3) 0.56
aChi-square test of association, comparing to controls.
bt-test for equality of means, comparing to controls.
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TABLE 2 | Association of antibodies and risk of ASD, distribution and crude odds ratios, EMA study, births 2000–2001.
N at MDL Category Analyte ASD Controls ORunadj 95% CI
MATERNAL
Total IgG (µg/ml) Q4 >53.63 18 36 0.77 (0.36, 1.66)
Q3 >46.59–53.63 28 37 1.17 (0.57, 2.37)
Q2 >43.11–46.59 14 37 0.58 (0.26, 1.30)
0 (Ref*) Q1 0–43.11 24 37
Total IgM (µg/ml) Q4 >65.96 15 35 0.55 (0.25, 1.19)
Q3 >56.80–65.96 18 38 0.60 (0.29, 1.27)
Q2 >29.56–56.80 22 37 0.76 (0.37, 1.56)
0 (Ref*) Q1 0–29.56 29 37
Toxo IgG (SI) Cat 4 >18.6 8 37 0.23 (0.09, 0.55)
Cat 3 >6.3–18.6 15 35 0.45 (0.21, 0.96)
Cat 2 >0–6.3 23 35 0.69 (0.35, 1.38)
78 (Ref**) Cat 1 0 38 40
Toxo IgM (odu***) Q4 >0.202 15 35 0.57 (0.26, 1.23)
Q3 >0.172–0.202 22 38 0.77 (0.38, 1.56)
Q2 >0.158–0.172 17 34 0.67 (0.32, 1.41)
0 (Ref*) Q1 0–0.158 30 40
NEWBORN
Total IgG (µg/ml) Q4 >61.18 18 38 0.66 (0.31, 1.38)
Q3 >55.03–61.18 16 38 0.59 (0.27, 1.25)
Q2 >51.63–55.03 18 38 0.66 (0.31, 1.38)
0 (Ref*) Q1 0–51.63 28 39
Total IgM (µg/ml) Cat2 >1.20 29 66 0.75 (0.43, 1.31)
0 (Ref**) Cat 1 0–1.20 51 87
Toxo IgG (odu***) Q4 >0.097 5 38 0.14 (0.05, 0.39)
Q3 >0.066–0.097 23 38 0.64 (0.32, 1.27)
Q2 >0.057–0.066 15 38 0.42 (0.20, 0.88)
0 (Ref*) Q1 0–0.057 37 39
*Reference quartile (Q1) includes signals at and above the MDL based on control values.
**Reference category (Cat 1) only includes signals at the MDL. Values above the MDL divided into equal-sized categories based on control values.
***Optical density units (blank adjusted).
Bold means statistically significant.
After adjustment for laboratory plate, maternal age, and
maternal education (Table 3Adj Column 1), maternal specimens
did not show significant difference between cases and controls
for total IgG, total IgM, or Toxo IgM, although, as in the
unadjusted analyses, virtually all point estimates were below
1.0. Higher levels of Toxo IgG were significantly associated
with lower risk of ASD (Category 4 vs. Category 1) and
the dose-response trend across the Toxo IgG categories
reached statistical significance (p = 0.038). With further
adjustment for maternal race-ethnicity (Table 3Adj Column 2),
the Toxo IgG results continued to indicate lower risk with
higher levels with a dose-response pattern (p = 0.039).
Further adjustment that included place of birth for white
Hispanic mothers (US-born or not US-born) showed
similar patterns that did not reach statistical significance
(Table 3Adj Column 3).
In adjusted models with newborn specimens, all ORs
were below 1.0, with the comparison of Toxo IgG Q4 vs. Q1
reaching statistical significance (Table 3Adj Columns 1 and 2).
No dose-response pattern for newborn Toxo IgG was
observed.
ASD with and without Intellectual Disability
Data on presence/absence of intellectual disability was available
on 76% of the children with ASD, permitting identification of
two subgroups: ASD with ID (n= 34) and ASD without ID (n=
30). Each of these subgroups was then compared separately to the
control group and the resulting ORs for each analyte compared
across the two subgroups. No statistically significant differences
between the two subgroups were observed (data not shown).
Small numbers of children precluded adjustment for covariates.
DD vs. Controls
In models adjusted for laboratory plate, gender, birth year, and
days to blood draw, we found no association between risk of DD
and any of the analytes when comparing the LOW and HIGH
exposure categories. Odds ratios for the different analytes ranged
from 0.71 to 1.28 with no apparent pattern and all confidence
intervals included the null value (data not shown).
Correlations within Mother-Baby Pairs
Within mother-baby pairs, levels of total IgG measured in
mothers during mid-gestation and in their newborns were not
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TABLE 3 | Association of antibodies and risk of ASD, EMA study, births 2000–2001.
ORa
adj
95% CI ORb
adj
95% CI ORc
adj
95% CI
MATERNAL
Total IgG
Q4 vs. Q1 0.92 (0.39, 2.17) 0.87 (0.37, 2.08) 0.89 (0.37, 2.13)
Q3 vs. Q1 1.41 (0.63, 3.14) 1.39 (0.62, 3.12) 1.34 (0.59, 3.01)
Q2 vs. Q1 0.53 (0.22, 1.30) 0.51 (0.21, 1.25) 0.51 (0.21, 1.27)
Total IgM
Q4 vs. Q1 0.46 (0.17, 1.27) 0.44 (0.16, 1.23) 0.42 (0.15, 1.21)
Q3 vs. Q1 0.63 (0.25, 1.61) 0.63 (0.25, 1.60) 0.71 (0.27, 1.85)
Q2 vs. Q1 0.68 (0.29, 1.62) 0.69 (0.29, 1.66) 0.75 (0.31, 1.82)
Toxo IgG
CAT4 vs. CAT1* 0.35 (0.13, 0.91) 0.33 (0.12, 0.86) 0.40 (0.15, 1.11)
CAT3 vs. CAT1* 0.58 (0.25, 1.32) 0.53 (0.22, 1.24) 0.55 (0.23, 1.30)
CAT2 vs. CAT1* 0.86 (0.40, 1.86) 0.83 (0.38, 1.81) 0.86 (0.39, 1.87)
Toxo IgM
Q4 vs. Q1 0.80 (0.32, 1.99) 0.78 (0.31, 1.94) 0.71 (0.28, 1.77)
Q3 vs. Q1 0.82 (0.36, 1.84) 0.78 (0.34, 1.78) 0.70 (0.30, 1.64)
Q2 vs. Q1 0.78 (0.33, 1.84) 0.74 (0.31, 1.78) 0.69 (0.28, 1.69)
NEWBORN
Total IgG
Q4 vs. Q1 0.77 (0.31, 1.89) 0.76 (0.31, 1.86) 0.70 (0.28, 1.76)
Q3 vs. Q1 0.65 (0.28, 1.48) 0.61 (0.27, 1.42) 0.64 (0.27, 1.48)
Q2 vs. Q1 0.75 (0.33, 1.69) 0.72 (0.32, 1.65) 0.72 (0.31, 1.66)
Total IgM
HIGH vs. LOW** 0.67 (0.30, 1.49) 0.67 (0.30, 1.48) 0.77 (0.34, 1.75)
Toxo IgG
Q4 vs. Q1 0.25 (0.08, 0.79) 0.25 (0.08, 0.78) 0.31 (0.10, 1.01)
Q3 vs. Q1 0.89 (0.41, 1.94) 0.90 (0.41, 1.96) 0.87 (0.39, 1.92)
Q2 vs. Q1 0.52 (0.23, 1.17) 0.52 (0.23, 1.18) 0.50 (0.22, 1.14)
aAdjusted for laboratory plate, maternal age, maternal education.
bAdjusted for laboratory plate, maternal age, maternal education, maternal race/ethnicity (White non-Hisp., White Hisp., Other).
cAdjusted for laboratory plate, maternal age, maternal education, maternal race/ethnicity (White non-Hisp., White Hisp.-US Born, White Hisp.-Not US Born, Other).
*Reference category (CAT1) only includes signals at the MDL. Values above the MDL divided into 3 equal-sized categories based on control values.
**Reference category (LOW) includes all signals above but close to the minimum observed value for the assay, with remaining values lumped into one higher category.
Bold means statistically significant.
correlated in the group of ASD cases (rϕ = −0.03), in controls
(rϕ = 0.04), or in the DD group (rϕ = 0.08). Similarly, IgM
showed no correlation between levels in maternal and newborn
specimens in the ASD group (rϕ =0.04), the control group
(rϕ = −0.03) or the DD group (rϕ = −0.0.26, p = 0.08). In
contrast, Toxo IgG levels in maternal and newborn specimens
were correlated within ASD cases (rϕ = 0.34, p < 0.002) and
within population controls (rϕ = 0.53, p < 0001) but not in the
DD group (rϕ = 0.11, p= 0.47).
To further explore an association between low Toxo IgG and
ASD, we evaluated mother-baby ASD and control pairs in which
both mother and newborn Toxo IgG levels were in the reference
range (see Table 2) compared to pairs in which either or both the
maternal or the newborn values were above the reference range.
The logistic model (adjusted for laboratory plate only) yielded an
OR of 0.24 (95% CI 0.10, 0.56), consistent with a lower risk of
ASD associated with higher levels of Toxo IgG.
DISCUSSION
This ASD case-control study is the first to report
immunoglobulin levels measured in both maternal
mid-gestational and newborn specimens from linked mother-
baby pairs. The immunoglobulins were selected based on our
prior California study using newborn specimens in which lower
risk of ASD was associated with higher assay levels for total IgG
and Toxo IgG (Grether et al., 2010).
The results reported here are consistent in many, but not all,
respects to those we reported earlier. In the current study, the
results for both total IgG and Toxo IgG suggest, but do not
statistically confirm, a lower risk of ASD associated with higher
levels of the analytes in newborn specimens, similar to the earlier
findings but not reaching statistical significance, perhaps because
of the smaller number of subjects available for this current study.
In the maternal specimens, lower risk of ASD appeared to be
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associated with higher measured levels of Toxo IgG, reaching
statistical significance for several comparisons with a dose-
response pattern indicating a protective association. However,
this association no longer reached statistical significance in
models controlling for maternal place of birth, suggesting that
the ASD case and controls differences we see with Toxo IgG may
be a function of place of birth, as country of origin is a significant
factor influencing exposure to Toxo (Jones et al., 2001).
The ORs for most comparisons, both maternal and newborn,
were substantially below the null value, suggesting an overall
pattern of lower measured levels of these immunoglobulins in
ASD mother-baby pairs, even though some risk estimates did
not reach statistical significance. Whether these patterns would
become more statistically robust with a larger number of subjects
cannot be determined from this one study. No differences
were detected in immunoglobulin levels between subgroups of
ASD defined by presence/ absence of intellectual disability, but
sample sizes were small. Analyses of the analytes in specimens
from a heterogeneous group of children with DD and their
mothers failed to show any associations or possible patterns when
compared to the controls, and small numbers of children with
DD prevented detailed analysis.
Within mother-baby pairs, the levels of total IgG for mothers
and their offspring were not statistically correlated for any of the
three groups of subjects; nor were mother-baby values correlated
for total IgM. Absence of correlation is, perhaps, not surprising
given the elapsed time between maternal mid-gestational and
newborn blood draws, the limitation of one time-point during
pregnancy, and the multitude of antigens and immune response
represented in these total measurements (Buka et al., 2001b). In
contrast, signals for antigen-specific Toxo IgG show moderate
and statistically significant correlation between maternal mid-
gestational and newborn values for both ASD and population
control pairs, despite the limitations related to time of specimen
collection. Within the context of this study, we are unable to
determine if the presence of Toxo IgG represents recent or distant
exposure (Toxo IgG can persist for several years), but to our
knowledge, none of the children in either the ASD or population
control groups showed clinical manifestations of congenital
Toxoplasmosis. For the DD group, no correlations were observed
withinmother-baby pairs for any analytes, perhaps because of the
greater number of children of low gestational age in this subgroup
(transfer of IgG antibodies from mother to baby occurs late in
gestation).
Because this study employs different specimens and assays
than those used in clinical settings, the clinical significance of
the differences observed here is unclear. However, the overall
consistency of our results with those found in our prior study
(Grether et al., 2010), of higher ASD risk associated with
lower immunoglobulin signals, is potentially informative. Taken
together, these results are consistent with the evidence from other
studies indicating that atypicalmaternal immune function during
fetal life may contribute in some way to the development of ASD
in a subset of children (Croen et al., 2008a; Goines et al., 2011;
Brown et al., 2014).
In the prior study, we raised the question of whether
the higher risk of ASD associated with lower newborn
immunoglobulin signals might represent impaired placental
transport. Based on the current study, this does not seem likely
since the ASD maternal specimens showed the same overall
pattern of lower immunoglobulin levels compared to controls as
seen in the newborn specimens.
A plausible explanation for lower immunoglobulin levels
associated with ASD is suboptimal function of the maternal
immune system; exposure to common antigens may not elicit
a full or typical maternal immune response, contributing to
development of ASD in offspring. Whether and how suboptimal
maternal immune function may impact fetal neurodevelopment
remains to be explicated. Another possible explanation is
that the lower immunoglobulin levels associated with ASD
may simply represent reduced maternal exposure to common
infectious agents. That some version of the “hygiene hypothesis”
during early neurodevelopment may be relevant to ASD risk
was previously offered by Becker (2007) based on parallel
epidemiological, morphometric, molecular, and genetic patterns
between ASD and other inflammatory disorders such as asthma.
Infants and young children who lack the robust immune
protection provided by maternally-derived immunoglobulins,
whether from suboptimal maternal immune function or reduced
maternal exposure, might be expected to be more vulnerable to
infectious exposures after birth, perhaps contributing to higher
risk for ASD. However, studies have failed to consistently show an
association between increased frequency of postnatal infectious
illnesses and risk for ASD (Rosen et al., 2007; Atladottir et al.,
2010, 2012b). Whether postnatal exposure to Toxoplasmosis as a
specific antigen may be related to higher risk for ASD has not, to
our knowledge, been investigated.
Animal studies have documented a link between maternal
infectious exposure (and non-infectious activation of the
maternal immune system) during pregnancy and autistic-like
behaviors in offspring (Patterson, 2011). A number of early
human studies also indicated that maternal infectious illnesses
during pregnancy, although uncommon, may be more frequent
in the history of children with ASD than in controls (Chess,
1971; Deykin andMacMahon, 1979; Markowitz, 1983; Yamashita
et al., 2003).More recent studies are inconsistent (Atladottir et al.,
2012a; Zerbo et al., 2013; Brown et al., 2014). Further studies
based on medical record documentation may be informative,
at least for more severe infections/fevers, as would prospective
studies that document maternal illness during pregnancy.
In interpreting the results of our study, several strengths and
limitations need to be considered. Strengths include population-
based identification of subjects and the prospective specimen
collection, permitting analysis of biological markers of infections
during early fetal and neonatal neurodevelopment. However, our
modest sample size limited our statistical power, especially for
DD group for which our null results may not be generalizable.
The diagnostic information we used to select the ASD and
DD groups relied on DDS service agency reports with expert
review by experienced clinicians. Other studies, in which the ASD
diagnosis has been validated through comprehensive clinical
assessment, have indicated a very high level of diagnostic validity
for children enrolled in DDS with an ASD (Hertz-Picciotto et al.,
2006; Croen et al., 2008b; Hallmayer et al., 2011). Our laboratory
Frontiers in Neuroscience | www.frontiersin.org 8 May 2016 | Volume 10 | Article 218
Grether et al. Perinatal Immunoglobulin Levels and Autism
assays were fully blinded to case-control status and conducted in
research laboratories with extensive experience in these research
assays. However, the assays are not comparable to clinical ones,
limiting our ability to interpret the biologic relevance of the
results in a clinical framework. Since we did not measure all
antigen-specific immunoglobulins, our results should not be
interpreted as ruling out the possibility that exposure to some
specific antigens not evaluated here might increase risk of ASD.
Bias related to laboratory procedures can reasonably be ruled
out as an explanation for our overall patterns of lower antibody
levels in the ASD group, but undetected bias in initial selection of
subjects must be considered as a possible explanation.
CONCLUSION
Taken as a whole, and if supported by further research, our results
suggest that early immunoglobulin patterns in ASDmother-baby
pairs may be etiologically informative; we recommend further
studies that include prenatal and newborn specimens from linked
mother-baby pairs to evaluate these immunoglobulins and other
immune markers and possible effect modification associated
with gene-pool factors or geographic differences in maternal
exposure.
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